CENTRAL PHARMACEUTICAL CPC1.JSC	***SOCIALIST REPUBLIC OF VIETNAM***
NO: 1412/CPC1-TCKT	*Independence – Freedom – Happiness*
Re: Explanation of the change in Profit after Corporate Income Tax in the Q2 2026 Statement of Income by 10% or more compared to Q2 2025	*Hanoi, 20 July 2026*

To: - State Securities Commission of Vietnam;
- Hanoi Stock Exchange.

Pursuant to Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance providing guidance on information disclosure in the securities market.

According to the Company's financial statements for the second quarter of 2026 and the second quarter of 2025, the Company's business performance is as follows:

- Profit after Corporate Income Tax for Q2 2026: VND 44.410 billion
- Profit after Corporate Income Tax for Q2 2025: VND 22.462 billion

The Profit after Corporate Income Tax in Q2 2026 increased by VND 21.947 billion, equivalent to an increase of 41%, compared to Q2 2025.

➢ Main reasons for the increase are as follows:

- Net revenue in Q2 2026 increased by VND 129.413 billion, or 13%, compared to Q2 2025. Cost of goods sold increased by VND 106.645 billion, or 12%. As a result, gross profit from sales of goods and rendering of services increased by VND 22.767 billion, equivalent to 14%, compared to the same period last year.
- Financial income in Q2 2026 decreased by VND 886.225 million, or 8%, compared to Q2 2025.
- Selling expenses in Q2 2026 increased by VND 2.542 billion, or 4%, compared to Q2 2025.

Based on the above factors, the Company's Profit after Corporate Income Tax for the second quarter of 2026 increased by VND 21.947 billion, equivalent to an increase of 41%, compared to the second quarter of 2025. This improvement was primarily attributable to the growth in net revenue, while the increase in the cost of goods sold was at a lower rate than the increase in net revenue, resulting in a VND 22.767 billion (14%) increase in gross profit from sales of goods and the provision of services. Although financial income decreased and selling expenses increased compared to the same period of the previous year, these factors only partially offset the overall increase in profit.

Central Pharmaceutical Joint Stock Company No.1 (CPC1) respectfully submits this explanation to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for their information.

Respectfully submitted!

DEPUTY GENERAL DIRECTOR

CÔNG TY CỔ PHẦN DƯỢC PHẨM TRUNG ƯƠNG CPC1

Nguyen Huy Thanh

Recipients:
- As above;
- Filed at: Administration Office, Finance & Accounting Department, Human Resources & Administration Department.